OptiBiotix Health PLC SlimBiome Medical manufacturing agreement (8053I)

TIDMOPTI

RNS Number : 8053I

OptiBiotix Health PLC

29 November 2018

29 November 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

SlimBiome Medical Exclusive Manufacturing Agreement

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant an exclusive license agreement to Nutrilinea S.R.L. ("Nutrilinea") for the production, packaging, and supply of SlimBiome Medical in Europe with the aim of maximizing the financial return for both parties. The agreement secures manufacturing for OptiBiotix's award winning SlimBiome(R) weight management product recently granted medical device status and CE mark (RNS: November 27(th) 2018). Nutrilinea will formulate and package SlimBiome(R) Medical in boxes of 30 single sachet doses for sale to its own European partners and OptiBiotix's growing list of existing and potential international partners.

Nutrilinea has over 15 years' experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea has established an international reputation for providing innovative product formulations and presentations and is one of Europe's fastest growing providers of food supplements with year on year growth of 30% over the last 5 years and revenues of EUR70m. Nutrilinea has become a valued partner of OptiBiotix and has been instrumental in the development of the Company's own brand CholBiome(R) and the rapid sales growth of OptiBitiox's LP-LDL products.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this exclusive license agreement with Nutrilinea for the manufacture and supply of SlimBiome(R) Medical as a clinically proven solution to support weight loss. We chose Nutrilinea due to their industry reputation, extensive European network and expertise in manufacture of high value food and medical products for Europe and the USA. We believe partners like Nutrilinea provide the best opportunity of building SlimBiome Medical into a global brand. We see CE marking and medical device registration as an exciting extension of SlimBiome(R) from food products into high value medical products in consumer healthcare and pharmaceutical markets which we hope will contribute substantive revenues to OptiBiotix's growth in the months and years ahead."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                           www.optibiotix.com 
 Stephen O'Hara, Chief Executive                               Contact via Walbrook 
                                                                              below 
 
 Cairn Financial Advisers LLP (NOMAD)                            Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty five international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGREASFPAEKPFFF

(END) Dow Jones Newswires

November 29, 2018 02:00 ET (07:00 GMT)